REG - ReNeuron Group plc - Clinical update and conference presentation

ReNeuronAnnouncement

04/04/2019 07:05

RNS Number : 1090V
ReNeuron Group plc
04 April 2019
 


 



4 April 2019


AIM: RENE



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Clinical update and conference presentation
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a further update on progress with the ongoing Phase 1/2 clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
 
The Company is pleased to confirm that the positive efficacy seen and previously announced has, to date, been sustained in the first patient cohort in the Phase 2 part of the study.  
 
In February this year, the Company reported that all three of the first cohort of subjects in the study had reported a rapid and significant improvement in vision, on average equivalent to reading an additional three lines of five letters on the EDTRS eye chart, the standardised eye chart used in clinical trials to measure visual acuity. 
 
Last month, the Company announced that dosing of the second cohort of three Phase 2 subjects had commenced in the study.  This next dose cohort comprises patients who have a greater baseline level of visual acuity than those treated in the study thus far.
 
Further read-outs from the patients treated in the Phase 1/2 study will be presented at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada, on 26 April 2019.  Information regarding this conference may be found at:
https://www.regonline.com/builder/site/default.aspx?EventID=2548135
 
The Company will make a further announcement later this month, when these further read-outs from the study are known.
 
The Company's RP clinical programme benefits from Orphan Drug Designation in both Europe and the US, as well as Fast Track designation from the FDA.   
 
Olav Hellebø, Chief Executive Officer of ReNeuron, said:
 
"We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing Phase 1/2 study with our hRPC cell therapy candidate for retinitis pigmentosa.  We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month."
 
 
ENDS
 
ENQUIRIES:
 



ReNeuron


 +44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer








Michael Hunt, Chief Financial Officer








 
Buchanan (UK)


 
+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham








 
Argot Partners (US)
Stephanie Marks, Claudia Styslinger
 
Stifel Nicolaus Europe Limited


     
  +1 212 600 1902
        
 
 +44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)








 
Nplus1 Singer Advisory LLP


 
+44 (0) 20 7496 3000




Aubrey Powell, Mark Taylor (Joint Broker)







 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUSSVRKUASRRR